Monoclonal antibody 11B2C7 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2

Patent metadata

Field	Value
Publication number	US-12098185-B2
Application number	US-201817272050-A
Country	US
Kind code	B2
Filing date	Aug 28, 2018
Priority date	Aug 28, 2018
Publication date	Sep 24, 2024
Grant date	Sep 24, 2024

Abstract

The present invention refers to a new monoclonal antibody or fragment thereof, called 11B2C7, which specifically recognizes herpes simplex virus (HSV), in its two types, herpes simplex virus type 1 and herpes simplex virus type 2 (HSV-1 and HSV-2). Preferably, the antibody of the invention is useful for the development of methods for the diagnosis of herpes simplex virus infection, as well as for the production of pharmaceutical compositions intended for the treatment, protection and/or prophylaxis of infection specifically caused by HSV-1 and HSV-2.

First claim

The invention claimed is:

1. A monoclonal antibody or an antigen-binding fragment thereof that specifically recognizes herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), wherein said antibody or the antigen-binding fragment thereof has a variable region of a heavy chain in which CDR1, CDR2, and CDR3 have amino acid sequences defined in SEQ ID No:3, SEQ ID No:4, and SEQ ID No: 5, respectively, and at the same time has a variable region of a light chain in which CDR1, CDR2, and CDR3 have amino acid sequences defined in SEQ ID No:6, SEQ ID No:7, and SEQ ID No:8, respectively.

2. The monoclonal antibody or the antigen-binding fragment thereof according to claim 1 , wherein said monoclonal antibody or the antigen-binding fragment thereof has the variable region of the heavy chain in which the CDR1, the CDR2, and the CDR3 are encoded by sequences that have at least 90% identity with SEQ ID No:11, SEQ ID No:12, and SEQ ID No: 13, respectively, and has the variable region of the light chain in which the CDR1, the CDR2, and the CDR3 are encoded by sequences that have at least 90% identity with SEQ ID No:14, SEQ ID No:15, and SEQ ID No:16, respectively.

3. The monoclonal antibody or the antigen-binding fragment thereof according to claim 1 , wherein the monoclonal antibody or the antigen-binding fragment thereof is specific against protein VP21 of a capsid of the HSV-1 and the HSV-2.

4. The monoclonal antibody or the antigen-binding fragment thereof according to claim 1 , wherein the antibody is a humanized or a chimeric antibody.

5. A pharmaceutical composition for treatment and/or prophylaxis of infection caused by HSV-1 and/or HSV-2, comprising:
the monoclonal antibody or the antigen-binding fragment thereof of claim 1 ; and
a pharmaceutically acceptable carrier.

6. A method for detection of HSV-1 and/or HSV-2 virus in a sample, comprising:
contacting the sample with the monoclonal antibody or the antigen-binding fragment thereof of claim 1 ; and
detecting a binding of the monoclonal antibody or the antigen-binding fragment thereof to the HSV-1 or the HSV-2 or both, as an antigen in the sample.

7. The method according to claim 6 , wherein the method used to detect the binding of the monoclonal antibody or the antigen-binding fragment thereof to the antigen is at least one technique selected from the group consisting of ELISA, immunofluorescence, immunohistochemistry, immunochromatography, flow cytometry, cell sorting, immunoprecipitation, and western blotting.

8. A method for detection of HSV-1 and/or HSV-2 virus in a sample, comprising:
contacting the sample with the monoclonal antibody or the antigen-binding fragment thereof according to claim 1 ; and
detecting a binding of the monoclonal antibody or the antigen binding fragment thereof to the HSV-1 or the HSV-2 or both, as an antigen in the sample, wherein the monoclonal antibody or the antigen-binding fragment thereof is conjugated with a marker that allows detection of a presence of the monoclonal antibody or the antigen-binding fragment thereof.

9. The method according to claim 8 , wherein the marker is a label selected from the group consisting of fluorophores, biotin, radioisotopes, metals, and enzymes.

10. The method according to claim 8 , wherein the monoclonal antibody or the antigen binding fragment thereof is immobilized on a solid support.

11. The method according to claim 10 , wherein the solid support is a support selected from the group consisting of nitrocellulose, cellulose, polyethylene, nylon, and other immunochromatography-compatible solid supports.

12. The method according to claim 6 , wherein the sample is a sample selected from the group consisting of a swab that has been contacted with mouth, skin, eye, or mucosa, samples of plasma or brain-spinal fluid, and any other samples in which presence of the HSV-1, or the HSV-2 virus, or both is suspected.

Assignees

• Univ Pontificia Catolica Chile
• Fundacion Copec Univ Catolica

Inventors

• Kalergis Parra Alexis
• Bueno Ramírez Susan
• Gonzalez Muñoz Pablo

Classifications

• G01N2333/035

  Herpes simplex virus I or II · CPC title

• G01N33/56994

  Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• G01N2469/10

  Detection of antigens from microorganism in sample from host · CPC title